Subtopic Deep Dive
Mechanisms of Resistance to CDK4/6 Inhibitors
Research Guide
What is Mechanisms of Resistance to CDK4/6 Inhibitors?
Mechanisms of resistance to CDK4/6 inhibitors involve acquired and intrinsic pathways in HR-positive advanced breast cancer that bypass cell cycle blockade by drugs like palbociclib, ribociclib, and abemaciclib.
Resistance mechanisms include RB1 loss, cyclin E amplification, and PI3K/AKT/mTOR pathway activation. Single-cell sequencing and CRISPR screens identify these pathways. Over 10 papers from 2009-2023, with Finn et al. (2009) at 1378 citations, detail preclinical evidence.
Why It Matters
Resistance limits progression-free survival gains from CDK4/6 inhibitors plus endocrine therapy, as shown in MONARCH 2 (Sledge et al., 2019, 931 citations) where abemaciclib extended survival but resistance emerged. Understanding bypass signaling like PI3K/AKT/mTOR (Glaviano et al., 2023, 1583 citations) informs combinations such as CDK4/6 inhibitors with PI3K inhibitors. This drives next-generation therapies in NCCN guidelines (Gradishar et al., 2020, 1606 citations) for HR-positive, HER2-negative advanced breast cancer.
Key Research Challenges
Identifying Intrinsic Resistance
Intrinsic resistance occurs in subsets of luminal ER-positive cells despite CDK4/6 sensitivity. Finn et al. (2009, 1378 citations) showed PD 0332991 preferentially inhibits proliferation but some lines resist. Single-cell analysis is needed to profile heterogeneity.
Decoding Acquired Bypass Pathways
Acquired resistance activates PI3K/AKT/mTOR or cyclin E after prolonged therapy. Turner et al. (2018, 1207 citations) reported progression on palbociclib-fulvestrant. RB reactivation strategies (Thangavel et al., 2011, 293 citations) face pathway redundancy challenges.
Developing Predictive Biomarkers
RB1 loss and cyclin E amplification predict resistance but lack clinical validation. O’Leary et al. (2016, 1113 citations) reviewed mechanisms without standardized tests. CRISPR screens (Gelbert et al., 2014, 555 citations) identify vulnerabilities needing translation.
Essential Papers
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. · 2020 · Breast Cancer Research · 2.4K citations
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · 2016 · Annals of Oncology · 2.0K citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · 2016 · New England Journal of Medicine · 1.9K citations
Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving r...
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham et al. · 2020 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the t...
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam et al. · 2023 · Molecular Cancer · 1.6K citations
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth...
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong et al. · 2021 · Signal Transduction and Targeted Therapy · 1.5K citations
Abstract Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kin...
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn, Judy Dering, Dylan Conklin et al. · 2009 · Breast Cancer Research · 1.4K citations
Abstract Introduction Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cycl...
Reading Guide
Foundational Papers
Start with Finn et al. (2009, 1378 citations) for CDK4/6 inhibition basics in ER-positive lines, then Thangavel et al. (2011, 293 citations) for RB reactivation in resistance, and Gelbert et al. (2014, 555 citations) for preclinical LY2835219 models.
Recent Advances
Study Turner et al. (2018, 1207 citations) for palbociclib OS data, Sledge et al. (2019, 931 citations) for abemaciclib in progressed disease, and Glaviano et al. (2023, 1583 citations) for PI3K bypass.
Core Methods
Selective CDK4/6 inhibitors (PD 0332991, LY2835219, palbociclib); cell line proliferation assays; combination with endocrine therapy; emerging CRISPR screens and pathway analysis.
How PapersFlow Helps You Research Mechanisms of Resistance to CDK4/6 Inhibitors
Discover & Search
Research Agent uses searchPapers for 'CDK4/6 resistance mechanisms breast cancer' yielding Finn et al. (2009), citationGraph to trace 1378 citations to Thangavel et al. (2011), and findSimilarPapers for RB1 loss papers. exaSearch uncovers preclinical models from Gelbert et al. (2014).
Analyze & Verify
Analysis Agent applies readPaperContent to extract resistance pathways from Turner et al. (2018), verifyResponse with CoVe to check RB1 loss claims against Finn et al. (2009), and runPythonAnalysis for survival curve meta-analysis from MONARCH 2 (Sledge et al., 2019). GRADE grading scores evidence as high for palbociclib OS benefits.
Synthesize & Write
Synthesis Agent detects gaps in PI3K combination trials post-Glaviano et al. (2023), flags contradictions between preclinical (Roberts et al., 2012) and clinical data (Hortobágyi et al., 2016). Writing Agent uses latexEditText for resistance pathway revisions, latexSyncCitations for 10+ papers, latexCompile for figures, and exportMermaid for signaling diagrams.
Use Cases
"Extract and plot progression-free survival data from CDK4/6 inhibitor trials in resistant breast cancer"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Hortobágyi 2016, Turner 2018) → runPythonAnalysis (pandas/matplotlib HR plot) → GRADE-verified statistical output with p-values.
"Write LaTeX review section on RB1 loss as resistance mechanism with citations"
Synthesis Agent → gap detection (Thangavel 2011) → Writing Agent → latexEditText (draft text) → latexSyncCitations (Finn 2009, O’Leary 2016) → latexCompile → PDF with compiled equations.
"Find code for CRISPR screens modeling CDK4/6 resistance"
Research Agent → searchPapers (Gelbert 2014) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on shared CRISPR analysis scripts → verified vulnerability models.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'CDK4/6 resistance', structures report with GRADE tables from Finn (2009) to Sledge (2019). DeepScan applies 7-step CoVe to verify PI3K bypass claims (Glaviano 2023) with checkpoint critiques. Theorizer generates hypotheses on cyclin E combos from citationGraph of Roberts (2012).
Frequently Asked Questions
What defines mechanisms of resistance to CDK4/6 inhibitors?
Resistance pathways bypass CDK4/6 blockade via RB1 loss, cyclin E amplification, or PI3K/AKT activation in HR-positive breast cancer (Finn et al., 2009; O’Leary et al., 2016).
What methods study these resistance mechanisms?
Preclinical models use PD 0332991 (palbociclib) on ER-positive lines (Finn et al., 2009); clinical trials track progression (Turner et al., 2018); CRISPR screens identify hits (Gelbert et al., 2014).
What are key papers on CDK4/6 inhibitor resistance?
Finn et al. (2009, 1378 citations) introduced selective inhibition; Turner et al. (2018, 1207 citations) showed OS in resistant settings; O’Leary et al. (2016, 1113 citations) reviewed mechanisms.
What open problems remain in CDK4/6 resistance research?
Validated biomarkers for RB1/cyclin E lack; combination timing post-progression unoptimized (Sledge et al., 2019); translation from preclinical screens to trials needed (Thangavel et al., 2011).
Research Advanced Breast Cancer Therapies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mechanisms of Resistance to CDK4/6 Inhibitors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Advanced Breast Cancer Therapies Research Guide